For example, prolonged low-dose corticosteroid therapy did not significantly reduce mortality in large septic shock trials [18,19]; resuscitation guided by peripheral perfusion targets (capillary refill time) conferred no survival advantage over lactate-guided resuscitation [20]; and the novel vasopressor angiotensin II improved blood pressure but not 28-day mortality in vasodilatory shock [21]. The gene discussed is AGT; the disease is Shock.